ARC-02 / Otsuka - LARVOL DELTA

Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech (GlobeNewswire) - "Taiho Pharmaceutical...and Araris Biotech AG...announced today that they have entered into a definitive agreement pursuant to which Taiho Pharmaceutical will fully acquire Araris (hereinafter 'the Acquisition'). Following necessary procedures, the Acquisition is expected to be completed in first half of 2025. The Acquisition follows a research collaboration between Taiho Pharmaceutical and Araris signed in November 2023. Under the terms of the agreement, Taiho Pharmaceutical will pay USD 400 million at closing, with the potential for additional milestone payments of up to USD 740 million....Araris is advancing three products for the treatment of hematological and solid tumors developed using its unique AraLinQ technology, which are currently in the preclinical stage. These products are anticipated to enter into clinical trials between 2025 and 2026."

M&A • New trial • Hematological Malignancies • Oncology • Solid Tumor

Araris Biotech AG to Present at the 22nd Annual PepTalk: Protein Science and Production Week (GlobeNewswire) - "Araris Biotech AG...announced that Bernd Schlereth, Ph.D., chief development officer, will deliver an oral presentation at the 22nd annual PepTalk: Protein Science and Production Week being held January 16- 20, 2023 in San Diego....ARC-02 demonstrated potent cytotoxicity in three different non-Hodgkin Lymphoma (NHL) cell lines, with similar potency to Polivy^® despite ARC-02’s having a lower drug load; ARC-02 was more stable than Polivy^® in mouse, monkey and human sera and demonstrated no payload deconjugation or linker cleavage under physiological conditions during an incubation of 2 weeks; Single dose treatment of ARC-02 induced effective and long-lasting tumor responses at 3-4x lower payload dose compared to Polivy^® in NHL tumor models; In vivo pharmacokinetic studies in mice, rats and monkeys demonstrated an antibody-like exposure profile of the ADC with no premature toxin loss in circulation."

Preclinical • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology